Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Aug 15;102(4):679–687. doi: 10.1172/JCI2614

Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.

D C Devor 1, B D Schultz 1
PMCID: PMC508929  PMID: 9710435

Abstract

We evaluated the acute effects of ibuprofen and salicylic acid on cAMP-mediated Cl- secretion (Isc) in both colonic and airway epithelia. In T84 cells, ibuprofen inhibited the forskolin-dependent Isc in a concentration-dependent manner, having an apparent Ki of 142 microM. Salicylic acid inhibited Isc with an apparent Ki of 646 microM. We determined whether ibuprofen would also inhibit the forskolin-stimulated Isc in primary cultures of mouse trachea epithelia (MTE) and human bronchial epithelia (HBE). Similar to our results in T84 cells, ibuprofen (500 microM) inhibited the forskolin-induced Isc in MTEs and HBEs by 59+/-4% (n = 11) and 39+/-6% (n = 8), respectively. Nystatin was employed to selectively permeabilize the basolateral or apical membrane to determine the effect of ibuprofen on apical Cl- (ICl) and basolateral K+ (IK) currents after stimulation by forskolin. After forskolin stimulation, ibuprofen (500 microM) reduced both the ICl and IK; reducing ICl and IK by 60 and 15%, respectively. To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated. Ibuprofen (300 microM) reduced CFTR Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3). Similarly, salicylic acid (3 mM) reduced CFTR Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4). Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane K+ channels. This may reduce their efficacy in conjunction with other therapeutic strategies designed to increase CFTR expression and/or function in secretory epithelia.

Full Text

The Full Text of this article is available as a PDF (323.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  2. Barton A. D., Ryder K., Lourenço R. V., Dralle W., Weiss S. G. Inflammatory reaction and airway damage in cystic fibrosis. J Lab Clin Med. 1976 Sep;88(3):423–426. [PubMed] [Google Scholar]
  3. Brooks S. P., Storey K. B. Bound and determined: a computer program for making buffers of defined ion concentrations. Anal Biochem. 1992 Feb 14;201(1):119–126. doi: 10.1016/0003-2697(92)90183-8. [DOI] [PubMed] [Google Scholar]
  4. Cheng S. H., Gregory R. J., Marshall J., Paul S., Souza D. W., White G. A., O'Riordan C. R., Smith A. E. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990 Nov 16;63(4):827–834. doi: 10.1016/0092-8674(90)90148-8. [DOI] [PubMed] [Google Scholar]
  5. Clària J., Serhan C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9475–9479. doi: 10.1073/pnas.92.21.9475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cromwell O., Walport M. J., Morris H. R., Taylor G. W., Hodson M. E., Batten J., Kay A. B. Identification of leukotrienes D and B in sputum from cystic fibrosis patients. Lancet. 1981 Jul 25;2(8239):164–165. doi: 10.1016/s0140-6736(81)90353-6. [DOI] [PubMed] [Google Scholar]
  7. Davies N. M. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum. 1995 Dec;38(12):1311–1321. doi: 10.1007/BF02049158. [DOI] [PubMed] [Google Scholar]
  8. Devor D. C., Singh A. K., Bridges R. J., Frizzell R. A. Modulation of Cl- secretion by benzimidazolones. II. Coordinate regulation of apical GCl and basolateral GK. Am J Physiol. 1996 Nov;271(5 Pt 1):L785–L795. doi: 10.1152/ajplung.1996.271.5.L785. [DOI] [PubMed] [Google Scholar]
  9. Devor D. C., Singh A. K., Bridges R. J., Frizzell R. A. Psoralens: novel modulators of Cl- secretion. Am J Physiol. 1997 Mar;272(3 Pt 1):C976–C988. doi: 10.1152/ajpcell.1997.272.3.C976. [DOI] [PubMed] [Google Scholar]
  10. Devor D. C., Singh A. K., Frizzell R. A., Bridges R. J. Modulation of Cl- secretion by benzimidazolones. I. Direct activation of a Ca(2+)-dependent K+ channel. Am J Physiol. 1996 Nov;271(5 Pt 1):L775–L784. doi: 10.1152/ajplung.1996.271.5.L775. [DOI] [PubMed] [Google Scholar]
  11. Devor D. C., Singh A. K., Gerlach A. C., Frizzell R. A., Bridges R. J. Inhibition of intestinal Cl- secretion by clotrimazole: direct effect on basolateral membrane K+ channels. Am J Physiol. 1997 Aug;273(2 Pt 1):C531–C540. doi: 10.1152/ajpcell.1997.273.2.C531. [DOI] [PubMed] [Google Scholar]
  12. Ford-Hutchinson A. W., Bray M. A., Doig M. V., Shipley M. E., Smith M. J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. doi: 10.1038/286264a0. [DOI] [PubMed] [Google Scholar]
  13. Hammerschmidt D. E. Leukocytes in lung injury. Chest. 1983 May;83(5 Suppl):16S–20S. doi: 10.1378/chest.83.5_supplement.16s. [DOI] [PubMed] [Google Scholar]
  14. Janoff A. Proteases and lung injury. A state-of-the-art minireview. Chest. 1983 May;83(5 Suppl):54S–58S. [PubMed] [Google Scholar]
  15. Jenkins A. P., Trew D. R., Crump B. J., Nukajam W. S., Foley J. A., Menzies I. S., Creamer B. Do non-steroidal anti-inflammatory drugs increase colonic permeability? Gut. 1991 Jan;32(1):66–69. doi: 10.1136/gut.32.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jurivich D. A., Pachetti C., Qiu L., Welk J. F. Salicylate triggers heat shock factor differently than heat. J Biol Chem. 1995 Oct 13;270(41):24489–24495. doi: 10.1074/jbc.270.41.24489. [DOI] [PubMed] [Google Scholar]
  17. Jurivich D. A., Sistonen L., Kroes R. A., Morimoto R. I. Effect of sodium salicylate on the human heat shock response. Science. 1992 Mar 6;255(5049):1243–1245. doi: 10.1126/science.1546322. [DOI] [PubMed] [Google Scholar]
  18. Knowles M. R., Clarke L. L., Boucher R. C. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med. 1991 Aug 22;325(8):533–538. doi: 10.1056/NEJM199108223250802. [DOI] [PubMed] [Google Scholar]
  19. Konstan M. W., Byard P. J., Hoppel C. L., Davis P. B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848–854. doi: 10.1056/NEJM199503303321303. [DOI] [PubMed] [Google Scholar]
  20. Konstan M. W., Hoppel C. L., Chai B. L., Davis P. B. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr. 1991 Jun;118(6):956–964. doi: 10.1016/s0022-3476(05)82218-8. [DOI] [PubMed] [Google Scholar]
  21. Konstan M. W., Vargo K. M., Davis P. B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186–192. doi: 10.1164/ajrccm/141.1.186. [DOI] [PubMed] [Google Scholar]
  22. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956–959. doi: 10.1126/science.8052854. [DOI] [PubMed] [Google Scholar]
  23. Lohrmann E., Burhoff I., Nitschke R. B., Lang H. J., Mania D., Englert H. C., Hropot M., Warth R., Rohm W., Bleich M. A new class of inhibitors of cAMP-mediated Cl- secretion in rabbit colon, acting by the reduction of cAMP-activated K+ conductance. Pflugers Arch. 1995 Feb;429(4):517–530. doi: 10.1007/BF00704157. [DOI] [PubMed] [Google Scholar]
  24. Mochizuki H., Morikawa A., Tokuyama K., Kuroume T., Chao A. C. The effect of non-steroidal anti-inflammatory drugs on the electrical properties of cultured dog tracheal epithelial cells. Eur J Pharmacol. 1994 Feb 3;252(2):183–188. doi: 10.1016/0014-2999(94)90595-9. [DOI] [PubMed] [Google Scholar]
  25. O'Driscoll B. R., Kay A. B. Leukotrienes and lung disease. Thorax. 1982 Apr;37(4):241–245. doi: 10.1136/thx.37.4.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pahl H. L., Baeuerle P. A. The ER-overload response: activation of NF-kappa B. Trends Biochem Sci. 1997 Feb;22(2):63–67. doi: 10.1016/s0968-0004(96)10073-6. [DOI] [PubMed] [Google Scholar]
  27. Rosenstein B. J., Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics. 1991 Feb;87(2):245–246. [PubMed] [Google Scholar]
  28. Scheiman J. M. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996 Jun;25(2):279–298. doi: 10.1016/s0889-8553(05)70247-8. [DOI] [PubMed] [Google Scholar]
  29. Schultz B. D., DeRoos A. D., Venglarik C. J., Singh A. K., Frizzell R. A., Bridges R. J. Glibenclamide blockade of CFTR chloride channels. Am J Physiol. 1996 Aug;271(2 Pt 1):L192–L200. doi: 10.1152/ajplung.1996.271.2.L192. [DOI] [PubMed] [Google Scholar]
  30. Schultz B. D., Venglarik C. J., Bridges R. J., Frizzell R. A. Regulation of CFTR Cl- channel gating by ADP and ATP analogues. J Gen Physiol. 1995 Mar;105(3):329–361. doi: 10.1085/jgp.105.3.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Smalley W. E., Griffin M. R. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am. 1996 Jun;25(2):373–396. doi: 10.1016/s0889-8553(05)70253-3. [DOI] [PubMed] [Google Scholar]
  32. Sordelli D. O., Cerquetti M. C., el-Tawil G., Ramwell P. W., Hooke A. M., Bellanti J. A. Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa. Eur J Respir Dis. 1985 Aug;67(2):118–127. [PubMed] [Google Scholar]
  33. Tabcharani J. A., Chang X. B., Riordan J. R., Hanrahan J. W. Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene. Nature. 1991 Aug 15;352(6336):628–631. doi: 10.1038/352628a0. [DOI] [PubMed] [Google Scholar]
  34. Vanderhoek J. Y., Bailey J. M. Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen. J Biol Chem. 1984 Jun 10;259(11):6752–6756. [PubMed] [Google Scholar]
  35. Venglarik C. J., Schultz B. D., DeRoos A. D., Singh A. K., Bridges R. J. Tolbutamide causes open channel blockade of cystic fibrosis transmembrane conductance regulator Cl- channels. Biophys J. 1996 Jun;70(6):2696–2703. doi: 10.1016/S0006-3495(96)79839-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Venglarik C. J., Schultz B. D., Frizzell R. A., Bridges R. J. ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism. J Gen Physiol. 1994 Jul;104(1):123–146. doi: 10.1085/jgp.104.1.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wangemann P., Wittner M., Di Stefano A., Englert H. C., Lang H. J., Schlatter E., Greger R. Cl(-)-channel blockers in the thick ascending limb of the loop of Henle. Structure activity relationship. Pflugers Arch. 1986;407 (Suppl 2):S128–S141. doi: 10.1007/BF00584942. [DOI] [PubMed] [Google Scholar]
  38. White M. M., Aylwin M. Niflumic and flufenamic acids are potent reversible blockers of Ca2(+)-activated Cl- channels in Xenopus oocytes. Mol Pharmacol. 1990 May;37(5):720–724. [PubMed] [Google Scholar]
  39. Yang Y., Devor D. C., Engelhardt J. F., Ernst S. A., Strong T. V., Collins F. S., Cohn J. A., Frizzell R. A., Wilson J. M. Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Hum Mol Genet. 1993 Aug;2(8):1253–1261. doi: 10.1093/hmg/2.8.1253. [DOI] [PubMed] [Google Scholar]
  40. Yang Y., Janich S., Cohn J. A., Wilson J. M. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9480–9484. doi: 10.1073/pnas.90.20.9480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zakrzewski J. T., Barnes N. C., Costello J. F., Piper P. J. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987 Sep;136(3):779–782. doi: 10.1164/ajrccm/136.3.779. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES